Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Vorinostat × Dermatologic × Clear all

Phase

Status

Completed 11 Terminated 5 Withdrawn 2 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Nivolumab 24 pembrolizumab 18 Ipilimumab 15 Temozolomide 13 toripalimab 9 Cyclophosphamide 9 Biopsy 9 Blood Specimen Collection 8 Dacarbazine 7 camrelizumab 6 Imiquimod 6 trametinib 5 fludarabine 5 dabrafenib 5 atezolizumab 5 aldesleukin 5 Cisplatin 5 Chemotherapy, Adjuvant 5 fludarabine phosphate 4 durvalumab 4 binimetinib 4 apatinib 4 Sorafenib 4 Interleukin-2 4 Injections 4 Gene Expression Profiling 4 Bevacizumab 4 Aminolevulinic Acid 4 palbociclib 3 methyl 5-aminolevulinate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02943642 2016-10-25

Resimmune®

Angimmune LLC

Phase 2 Unknown

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡